NCT02264873View on ClinicalTrials.gov

Phase I, Dose Escalation Study of Decitabine

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

September 18, 2018

Conditions
Leukemia, Lymphoblastic, AcuteLeukemia, Myeloid AcuteHematopoetic Myelodysplasia
Interventions
DRUG

Decitabine

Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.

Trial Locations (1)

32610

UF Health Shands Hospital, Gainesville

All Listed Sponsors
collaborator

Hyundai Hope On Wheels

OTHER

lead

University of Florida

OTHER

NCT02264873 - Phase I, Dose Escalation Study of Decitabine | Biotech Hunter | Biotech Hunter